A deep survival analysis method based on ranking.

Journal: Artificial intelligence in medicine
Published Date:

Abstract

Survival analyses of populations and the establishment of prognoses for individual patients are important activities in the practice of medicine. Standard survival models, such as the Cox proportional hazards model, require extensive feature engineering or prior knowledge to model at an individual level. Some survival analysis models can avoid these problems by using machine learning extended the CPH model, and higher performance has been reported. In this paper, we propose an innovative loss function that is defined as the sum of an extended mean squared error loss and a pairwise ranking loss based on ranking information on survival data. We apply this loss function to optimize a deep feed-forward neural network (RankDeepSurv), which can be used to model survival data. We demonstrate that the performance of our model, RankDeepSurv, is superior to that of other state-of-the-art survival models based on an analysis of 4 public medical clinical datasets. When modelling the prognosis of nasopharyngeal carcinoma (NPC), RankDeepSurv achieved better prognostic accuracy than the CPH established by clinical experts. The difference between high and low risk groups in the RankDeepSurv model is greater than the difference in the CPH. The results show that our method has considerable potential to model survival data in medical settings.

Authors

  • Bingzhong Jing
    State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, P. R. China.
  • Tao Zhang
    Department of Traumatology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine, Chongqing University, Chongqing, 40044, People's Republic of China.
  • Zixian Wang
    State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou 510060, China; Department of Medical Oncology, Sun Yat-sen University Cancer Centre, Guangzhou, 510060, China.
  • Ying Jin
    Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, PR China.
  • Kuiyuan Liu
    State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, P. R. China.
  • Wenze Qiu
    State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, P. R. China.
  • Liangru Ke
    State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, P. R. China.
  • Ying Sun
    CFAR and I2R, Agency for Science, Technology and Research, Singapore.
  • Caisheng He
    State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, P. R. China.
  • Dan Hou
    Deepaint Intelligence Technology Co., Ltd., Guangzhou, 510080, China.
  • Linquan Tang
    State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, P. R. China.
  • Xing Lv
    State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, P. R. China. lvxing@sysucc.org.cn.
  • Chaofeng Li
    State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, P. R. China.